## HIGHLIGHTS

2387  Selected Articles from This Issue

## COMMENTARY

2389  Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success  
Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Houston, Jamie L. Studts, and Laura D. Scherer

2454  Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network  
Prostate Cancer Collaborative Group Review  
Michael A. Liss, Robin J. Leach, Martin G. Snda, and Oliver J. Semmes

## CEBP FOCUS

2396  The National Cancer Institute Early Detection Research Network: Two Decades of Progress  
Robert C. Bast Jr and Sudhir Srivastava

2401  The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers  
Sudhir Srivastava and Paul D. Wagner

2411  Biomarkers for Lung Cancer Screening and Detection  
Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash

2416  Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation  
Maria Farooq and James G. Herman

2423  Lung Cancer and Immunity Markers  
Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett

2431  Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation  
Robert S. Bresalier, William M. Grady, Sanford D. Markowitz, Hans Jørgen Nielsen, Surinder K. Batra, and Paul D. Lampe

2441  Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia  
Joshua D. Cohen, Brenda Diergaarde, Nickolas Papadopoulos, Kenneth W. Kinzler, and Robert E. Schoen

2463  The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment  
Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman

2475  Autoantibodies in Early Detection of Breast Cancer  
Femina Rauf, Karen S. Anderson, and Joshua LaBaer

2486  Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers  
William M. Grady, Ming Yu, Sanford D. Markowitz, and Amitabh Chak

2495  Biomarkers for the Early Detection of Hepatocellular Carcinoma  
Neelam D. Parikh, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok

2504  Biomarkers and Strategies for Early Detection of Ovarian Cancer  
Robert C. Bast Jr, Zhen Lu, Chae Young Han, Karen H. Lu, Karen S. Anderson, Charles W. Drescher, and Steven J. Skates

2513  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN  
Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrmann, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singh, Randall E. Brand, Anirban Maitra, and Brian B. Haab
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2693</td>
<td>Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp</td>
<td>Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O’Connell, Mingyang Song, Kana Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor</td>
</tr>
<tr>
<td>2702</td>
<td>Evaluation of Circulating Tumor DNA for Methylated BCAI and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)</td>
<td>Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marissa Hill, Iftekhhar Khan, Samith T. Kochuparambil, Susan E. Lyons, James Orsini Jr, Susanne K. Pedersen, Bruce Robb, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young</td>
</tr>
</tbody>
</table>

**NULL RESULTS IN BRIEF**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**ASPO REPORT**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2740</td>
<td>The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology</td>
<td>Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, "Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review," by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.